NDIVIDUALS WITH MODERATE TOsevere renal disease have an impaired ability to excrete phosphorus. As a result, they tend to develop hyperphosphatemia, especially in settings of high phosphorus intake. Elevated serum phosphorus levels are independently associated with increased mortality and morbidity. For example, serum phosphorus levels greater than the 5.5-mg/dL level recommended by practice guidelines are independently associated with a 20% to 40% increase in mortality risk among patients with end-stage renal disease (ESRD). [1][2][3][4][5][6][7][8][9] In addition, hyperphosphatemia appears to be involved in the development of atherosclerotic heart disease, secondary hyperparathyroidism, and bone disease among renal patients. [10][11][12] High phosphorus intake may also be detrimental for the general public. The dietary phosphorus intake of individuals in the United States has been in-creasing, while intake of calcium has been decreasing. 13 There is evidence to suggest that these intake patterns in-terfere with the normal process of calcium regulation and affect both peak bone mass and rate of bone loss, even See also Patient Page.
SummaryBackground and objectives Many patients with ESRD, particularly minorities and women, face barriers in completing the steps required to obtain a transplant. These eight sequential steps are as follows: medical suitability, interest in transplant, referral to a transplant center, first visit to center, transplant workup, successful candidate, waiting list or identify living donor, and receive transplant. This study sought to determine the effect of navigators on completion of steps.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.